Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
复制标题
DOI:
10.1172/jci.insight.156057
复制
发表时间:
2023-03-22
期刊:
影响因子:
8
通讯作者:
Sterneck, Esta
中科院分区:
文献类型:
--
作者:
Balamurugan, Kuppusamy;Poria, Dipak K.;Sehareen, Saadiya W.;Krishnamurthy, Savitri;Tang, Wei;McKennett, Lois;Padmanaban, Veena;Czarra, Kelli;Ewald, Andrew J.;Ueno, Naoto T.;Ambs, Stefan;Sharan, Shikha;Sterneck, Esta
Metastatic progression of epithelial cancers can be associated with epithelial-mesenchymal transition (EMT) including transcriptional inhibition of E-cadherin (CDH1) expression. Recently, EM plasticity (EMP) and E-cadherin–mediated, cluster-based metastasis and treatment resistance have become more appreciated. However, the mechanisms that maintain E-cadherin expression in this context are less understood. Through studies of inflammatory breast cancer (IBC) and a 3D tumor cell “emboli” culture paradigm, we discovered that cyclooxygenase 2 (COX-2; PTGS2), a target gene of C/EBPδ (CEBPD), or its metabolite prostaglandin E2 (PGE2) promotes protein stability of E-cadherin, β-catenin, and p120 catenin through inhibition of GSK3β. The COX-2 inhibitor celecoxib downregulated E-cadherin complex proteins and caused cell death. Coexpression of E-cadherin and COX-2 was seen in breast cancer tissues from patients with poor outcome and, along with inhibitory GSK3β phosphorylation, in patient-derived xenografts (PDX) including triple negative breast cancer (TNBC).Celecoxib alone decreased E-cadherin protein expression within xenograft tumors, though CDH1 mRNA levels increased, and reduced circulating tumor cell (CTC) clusters. In combination with paclitaxel, celecoxib attenuated or regressed lung metastases. This study has uncovered a mechanism by which metastatic breast cancer cells can maintain E-cadherin–mediated cell-to-cell adhesions and cell survival, suggesting that some patients with COX-2+/E-cadherin+ breast cancer may benefit from targeting of the PGE2 signaling pathway.
登录
查看更多内容
影响因子:
3.7
作者:
Fouad TM;Ueno NT;Yu RK;Ensor JE;Alvarez RH;Krishnamurthy S;Lucci A;Reuben JM;Yang W;Willey JS;Valero V;Bondy ML;Cristofinalli M;Shete S;Woodward WA;El-Zein R
通讯作者:
El-Zein R
影响因子:
3.8
作者:
Glynn SA;Prueitt RL;Ridnour LA;Boersma BJ;Dorsey TM;Wink DA;Goodman JE;Yfantis HG;Lee DH;Ambs S
通讯作者:
Ambs S
影响因子:
2
作者:
De Cremoux, Patricia;Hamy, Anne-Sophie;Bieche, Ivan
通讯作者:
Bieche, Ivan
DOI:
10.1073/pnas.1524448113
发表时间:
2016-05-03
影响因子:
11.1
作者:
Au, Sam H.;Storey, Brian D.;Toner, Mehmet
通讯作者:
Toner, Mehmet
影响因子:
16.6
作者:
通讯作者:
--